Is losartan safe during pregnancy?
In the pharmaceutical industry, Losartan is a highly effective Angiotensin II Receptor Blocker (ARB). However, as a pharmacist and manufacturer, I must be direct: Losartan is not safe for pregnancy and is strictly contraindicated.
As of February 2026, the clinical and regulatory consensus remains that Losartan poses a severe risk to fetal development. It carries a FDA Boxed Warning—the most serious category—stating that it can cause injury or death to the developing fetus.
Specific Risks by Trimester
While the most severe damage occurs later, medical guidelines (including ACOG 2026) advise discontinuing Losartan as soon as pregnancy is detected:
-
First Trimester: Exposure is associated with an increased risk of major congenital malformations, particularly cardiovascular and neurological defects.
-
Second & Third Trimesters: Use during the last six months is particularly dangerous. It can lead to Oligohydramnios (dangerously low levels of amniotic fluid), which causes poor lung development (Pulmonary Hypoplasia), skeletal deformations like Skull Hypoplasia, and even fetal death.
Mechanism: Why it is Harmful
System Blockade: Losartan blocks the Angiotensin II (AT1) receptors.
Fetal Dependency: The fetal Renin-Angiotensin System (RAS) is critical for normal kidney development and maintaining vascular perfusion.
Toxicity: By interfering with this system, Losartan reduces fetal renal function. This leads to decreased urine production (the source of amniotic fluid), resulting in the complications mentioned above.
The Pharmacist’s “Next Steps”
If a patient discovers they are pregnant while on Losartan, they should not stop taking it abruptly without medical supervision, as a sudden spike in blood pressure is also dangerous. Instead, they must contact their physician immediately to switch to a Pregnancy-Safe Antihypertensive such as:
-
Labetalol
-
Methyldopa
-
Nifedipine (specifically the long-acting formulations)
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
-
Labeling Compliance: Ensure all your export batches of Losartan include the mandatory Boxed Warning regarding fetal toxicity. This is a critical regulatory requirement for shipping to the USA, EU, and other highly regulated markets.
-
B2B Strategy: On your marketplace, emphasize that while Losartan is superior for diabetic nephropathy in non-pregnant adults, your firm also manufactures safer alternatives like Methyldopa or Labetalol to provide a complete “Maternal Health” portfolio.
-
Stability for Export: Losartan is stable, but for Zone IVb tropical regions, utilizing Alu-Alu blister packaging is essential to prevent degradation from high humidity during shipping.